Adriana Olar

Summary

Affiliation: The Methodist Hospital
Country: USA

Publications

  1. doi request reprint Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
    Adriana Olar
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX, USA
    Ann Diagn Pathol 16:161-70. 2012
  2. doi request reprint Biomarkers classification and therapeutic decision-making for malignant gliomas
    Adriana Olar
    Department of Pathology and Genomic Medicine, The Methodist Hospital, 6565 Fannin St, M227, Houston, TX 77030, USA
    Curr Treat Options Oncol 13:417-36. 2012
  3. doi request reprint Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma
    Aditya Raghunathan
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Diagn Pathol 16:255-9. 2012
  4. pmc Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma
    Adriana Olar
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Brain Pathol 25:266-75. 2015
  5. pmc C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma
    David Cachia
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Brain Tumor Pathol 32:105-11. 2015
  6. pmc Using the molecular classification of glioblastoma to inform personalized treatment
    Adriana Olar
    Department of Pathology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA
    J Pathol 232:165-77. 2014
  7. pmc IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
    Adriana Olar
    Department of Pathology, G1 3510, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Acta Neuropathol 129:585-96. 2015

Detail Information

Publications7

  1. doi request reprint Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults
    Adriana Olar
    Department of Pathology and Genomic Medicine, The Methodist Hospital, Houston, TX, USA
    Ann Diagn Pathol 16:161-70. 2012
    ..The shorter interval of progression and negative IDH1-R132H mutation status suggest a similar molecular pathway as seen in primary GBM...
  2. doi request reprint Biomarkers classification and therapeutic decision-making for malignant gliomas
    Adriana Olar
    Department of Pathology and Genomic Medicine, The Methodist Hospital, 6565 Fannin St, M227, Houston, TX 77030, USA
    Curr Treat Options Oncol 13:417-36. 2012
    ....
  3. doi request reprint Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma
    Aditya Raghunathan
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Diagn Pathol 16:255-9. 2012
    ..The absence of mutant IDH1 R132H protein expression in AG may help further distinguish this unique neoplasm from diffuse glioma...
  4. pmc Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma
    Adriana Olar
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Brain Pathol 25:266-75. 2015
    ..The results suggest that the use of a robust mitotic marker in meningioma could refine risk stratification. ..
  5. pmc C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma
    David Cachia
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Brain Tumor Pathol 32:105-11. 2015
    ....
  6. pmc Using the molecular classification of glioblastoma to inform personalized treatment
    Adriana Olar
    Department of Pathology, University of Texas MD Anderson Cancer Centre, Houston, TX, USA
    J Pathol 232:165-77. 2014
    ..In this paper we review basic glioblastoma pathophysiology, with emphasis on clinically relevant genetic molecular alterations and potential targets for further drug development...
  7. pmc IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas
    Adriana Olar
    Department of Pathology, G1 3510, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Acta Neuropathol 129:585-96. 2015
    ..Further evaluation of grading criteria and prognostic markers is warranted within IDH-mutant versus IDH-wild type diffuse grade II-III gliomas as independent entities. ..